ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
4.140
+0.940 (29.37%)
Aug 14, 2025, 1:57 PM - Market open
ReShape Lifesciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for ReShape Lifesciences.
Price Target: $ (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for ReShape Lifesciences.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 17, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $398,750 → $337,125 | Strong Buy | Maintains | $398,750 → $337,125 | +8,143,015.94% | May 26, 2022 |
| Maxim Group | Maxim Group | Strong Buy Initiates $580,000 | Strong Buy | Initiates | $580,000 | +14,009,561.84% | Oct 8, 2021 |
Financial Forecast
Revenue This Year
12.23M
from 8.01M
Increased by 52.80%
Revenue Next Year
n/a
from 12.23M
EPS This Year
-0.37
from -345.73
EPS Next Year
n/a
from -0.37
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 |
|---|---|
| High | 12.6M |
| Avg | 12.2M |
| Low | 11.8M |
Revenue Growth
| Revenue Growth | 2025 |
|---|---|
| High | 57.3% |
| Avg | 52.8% |
| Low | 46.8% |
EPS Forecast
| EPS | 2025 |
|---|---|
| High | -0.38 |
| Avg | -0.37 |
| Low | -0.35 |
EPS Growth
| EPS Growth | 2025 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.